3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio

Abstrakt

cytochrome P450 2D, genetic polymorphism, clinical evaluation, 4-hydroxylation, hydroxylation, oxidation, sulfates, nortriptyline, population genotypes